646 related articles for article (PubMed ID: 28865098)
1. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor.
Takeuchi T; Takahashi Y; Kawaguchi S; Ota K; Harada S; Kojima Y; Sakamoto H; Kuramoto T; Kojima K; Sanomura M; Hoshimoto M; Higashino T; Itabashi T; Takada K; Sakaguchi M; Tominaga K; Kusano M; Higuchi K
J Gastroenterol Hepatol; 2018 Mar; 33(3):623-630. PubMed ID: 28865098
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors : Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study.
Takeuchi T; Hongo H; Kimura T; Kojima Y; Harada S; Ota K; Takeuchi N; Noguchi T; Inoue T; Murano M; Higuchi K
J Gastroenterol; 2019 Nov; 54(11):972-983. PubMed ID: 31037449
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of acotiamide in combination with esomeprazole for functional dyspepsia refractory to proton-pump inhibitor monotherapy.
Mayanagi S; Kishino M; Kitagawa Y; Sunamura M
Tohoku J Exp Med; 2014 Nov; 234(3):237-40. PubMed ID: 25382232
[TBL] [Abstract][Full Text] [Related]
4. Improvement of meal-related symptoms and epigastric pain in patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan.
Yamawaki H; Futagami S; Kawagoe T; Maruki Y; Hashimoto S; Nagoya H; Sato H; Kodaka Y; Gudis K; Akamizu T; Sakamoto C; Iwakiri K
Neurogastroenterol Motil; 2016 Jul; 28(7):1037-47. PubMed ID: 26920949
[TBL] [Abstract][Full Text] [Related]
5. Sleep disturbances and refractory gastroesophageal reflux disease symptoms in patients receiving once-daily proton pump inhibitors and efficacy of twice-daily rabeprazole treatment.
Fujiwara Y; Habu Y; Ashida K; Kusano M; Higuchi K; Arakawa T
Digestion; 2013; 88(3):145-52. PubMed ID: 24008338
[TBL] [Abstract][Full Text] [Related]
6. Effects of acotiamide on functional dyspepsia patients with heartburn who failed proton pump inhibitor treatment in Japanese patients: A randomized, double-blind, placebo-controlled crossover study.
Funaki Y; Ogasawara N; Kawamura Y; Yoshimine T; Tamura Y; Izawa S; Ebi M; Sasaki M; Kasugai K
Neurogastroenterol Motil; 2020 Feb; 32(2):e13749. PubMed ID: 31612597
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment prediction of symptom response to proton pump inhibitor therapy.
Nagahara A; Miwa H; Asaoka D; Shimada Y; Sasaki H; Matsumoto K; Osada T; Hojo M; Watanabe S
J Gastroenterol Hepatol; 2015 Mar; 30 Suppl 1():25-30. PubMed ID: 25827800
[TBL] [Abstract][Full Text] [Related]
9. Proton pump inhibitor monotherapy is effective to attenuate dyspepsia symptoms associated with gastroesophageal reflux disease: a multicenter prospective observational study.
Isshi K; Matsuhashi N; Joh T; Higuchi K; Iwakiri K; Kamiya T; Manabe N; Ogawa M; Arihiro S; Haruma K; Nakada K
J Gastroenterol; 2019 Jun; 54(6):492-500. PubMed ID: 30673836
[TBL] [Abstract][Full Text] [Related]
10. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan.
Furuta T; Shimatani T; Sugimoto M; Ishihara S; Fujiwara Y; Kusano M; Koike T; Hongo M; Chiba T; Kinoshita Y;
J Gastroenterol; 2011 Nov; 46(11):1273-83. PubMed ID: 21861141
[TBL] [Abstract][Full Text] [Related]
11. Adding Acotiamide to Gastric Acid Inhibitors Is Effective for Treating Refractory Symptoms in Patients with Non-erosive Reflux Disease.
Yamashita H; Okada A; Naora K; Hongoh M; Kinoshita Y
Dig Dis Sci; 2019 Mar; 64(3):823-831. PubMed ID: 30465175
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and symptom pattern of pathologic esophageal acid reflux in patients with functional dyspepsia based on the Rome III criteria.
Xiao YL; Peng S; Tao J; Wang AJ; Lin JK; Hu PJ; Chen MH
Am J Gastroenterol; 2010 Dec; 105(12):2626-31. PubMed ID: 20823838
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study.
Kinoshita Y; Kato M; Fujishiro M; Masuyama H; Nakata R; Abe H; Kumagai S; Fukushima Y; Okubo Y; Hojo S; Kusano M
J Gastroenterol; 2018 Jul; 53(7):834-844. PubMed ID: 29188387
[TBL] [Abstract][Full Text] [Related]
14. Causal effect of anxiety and depression status on the symptoms of gastroesophageal reflux disease and functional dyspepsia during proton pump inhibitor therapy.
Nakada K; Oshio A; Matsuhashi N; Iwakiri K; Kamiya T; Manabe N; Joh T; Higuchi K; Haruma K
Esophagus; 2023 Apr; 20(2):309-316. PubMed ID: 36251168
[TBL] [Abstract][Full Text] [Related]
15. Proton pump inhibitors improve acid-related dyspepsia in gastroesophageal reflux disease patients.
Kusano M; Shimoyama Y; Kawamura O; Maeda M; Kuribayashi S; Nagoshi A; Zai H; Moki F; Horikoshi T; Toki M; Sugimoto S; Mori M
Dig Dis Sci; 2007 Jul; 52(7):1673-7. PubMed ID: 17385034
[TBL] [Abstract][Full Text] [Related]
16. A Randomized, Double-Blind, Pilot Study of the Effect of Famotidine on Acotiamide Treatment for Functional Dyspepsia.
Hojo M; Nagahara A; Asaoka D; Takeda T; Izumi K; Matsumoto K; Ueyama H; Shimada Y; Matsumoto K; Nojiri S; Watanabe S
Digestion; 2017; 96(1):5-12. PubMed ID: 28605740
[TBL] [Abstract][Full Text] [Related]
17. Validation of a short questionnaire in English and French for use in patients with persistent upper gastrointestinal symptoms despite proton pump inhibitor therapy: the PASS (Proton pump inhibitor Acid Suppression Symptom) test.
Armstrong D; Veldhuyzen SJ; Chung SA; Shapiro CM; Dhillon S; Escobedo S; Chakraborty BK; Mann V; Tanser L; Nevin K
Can J Gastroenterol; 2005 Jun; 19(6):350-8. PubMed ID: 15997268
[TBL] [Abstract][Full Text] [Related]
18. Observational comparative trial of the efficacy of proton pump inhibitors versus histamine-2 receptor antagonists for uninvestigated dyspepsia.
Nagahara A; Asaoka D; Hojo M; Oguro M; Shimada Y; Ishikawa D; Osada T; Kawabe M; Yoshizawa T; Otaka M; Watanabe S
J Gastroenterol Hepatol; 2010 May; 25 Suppl 1():S122-8. PubMed ID: 20586853
[TBL] [Abstract][Full Text] [Related]
19. Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan.
Tominaga K; Iwakiri R; Fujimoto K; Fujiwara Y; Tanaka M; Shimoyama Y; Umegaki E; Higuchi K; Kusano M; Arakawa T;
J Gastroenterol; 2012 Mar; 47(3):284-92. PubMed ID: 22081052
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of Yukgunja-tang combined with a proton pump inhibitor for refractory gastroesophageal reflux disease: study protocol for randomized, double-blind, double-dummy clinical trial.
Ha NY; Kim JW; Kim J
BMC Complement Med Ther; 2023 Dec; 23(1):444. PubMed ID: 38062418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
